Adverum Biotechnologies - ADVM Sales Growth YoY (Last Twelve Months)

Public company logo of Adverum Biotechnologies, Inc. (ADVM)

High patent barriers and strict FDA oversight protect Adverum Biotechnologies (ADVM) developments in macular dystrophy therapy. The annual revenue growth trend over a rolling 12-month period on the GURU.Markets chart shows volatility, where the -99.90 mark serves as a key metric. The business relies on partnerships with ophthalmology centers, and the high macro-resilience of gene biotech makes the company independent of economic cycles and seasonality.

Adverum Biotechnologies (ADVM) Sales Growth YoY (Last Twelve Months): for the period 02/11/2024 - 12/20/2025

Summary analytical data breakdowns for Adverum Biotechnologies (ADVM)

- share price and expert price forecast:
Fundamental company valuation:adverum.com
Original product of Adverum

This indicator measures revenue dynamics via a one-year rolling window to minimize data time asymmetry. For Adverum Biotechnologies (ADVM), the percentage change in sales over the last 12 months compared to the previous 12 months reflects the pre-commercial development stage of its gene therapy. The absence of current market levers makes this chart an indicator of early-stage scaling. It is critical for investors to benchmark growth rates against operating expenses, as this determines the company's fundamental stability.